Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | El-Shemi, A. Galal | - |
dc.contributor.author | Ashshi, A. Mohammed | - |
dc.contributor.author | Oh, E. | - |
dc.contributor.author | Jung, B-K | - |
dc.contributor.author | Basalamah, M. | - |
dc.contributor.author | Alsaegh, A. | - |
dc.contributor.author | Yun, C-O | - |
dc.date.accessioned | 2021-07-30T05:24:48Z | - |
dc.date.available | 2021-07-30T05:24:48Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 0969-7128 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4749 | - |
dc.description.abstract | Current treatments of hepatocellular carcinoma (HCC) are ineffective and unsatisfactory in many aspects. Cancer-targeting gene virotherapy using oncolytic adenoviruses (OAds) armed with anticancer genes has shown efficacy and safety in clinical trials. Nowadays, both inhibitor of growth 4 (ING4), as a multimodal tumor suppressor gene, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), as a potent apoptosis-inducing gene, are experiencing a renaissance in cancer gene therapy. Herein we investigated the antitumor activity and safety of mono-and combined therapy with OAds armed with ING4 (Ad-Delta B/ING4) and TRAIL (Ad-Delta B/TRAIL) gene, respectively, on preclinical models of human HCC. OAd-mediated expression of ING4 or TRAIL transgene was confirmed. Ad-Delta B/TRAIL and/or Ad-Delta B/ING4 exhibited potent killing effect on human HCC cells (HuH7 and Hep3B) but not on normal liver cells. Most importantly, systemic therapy with Ad-Delta B/ING4 plus Ad-Delta B/TRAIL elicited more eradicative effect on an orthotopic mouse model of human HCC than their monotherapy, without causing obvious overlapping toxicity. Mechanistically, Ad-Delta B/ING4 and Ad-Delta B/TRAIL were remarkably cooperated to induce antitumor apoptosis and immune response, and to repress tumor angiogenesis. This is the first study showing that concomitant therapy with Ad-Delta B/ING4 and Ad-Delta B/TRAIL may provide a potential strategy for HCC therapy and merits further investigations to realize its possible clinical translation. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.title | Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, C-O | - |
dc.identifier.doi | 10.1038/gt.2017.86 | - |
dc.identifier.scopusid | 2-s2.0-85042166292 | - |
dc.identifier.wosid | 000425100100008 | - |
dc.identifier.bibliographicCitation | GENE THERAPY, v.25, no.1, pp.54 - 65 | - |
dc.relation.isPartOf | GENE THERAPY | - |
dc.citation.title | GENE THERAPY | - |
dc.citation.volume | 25 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 54 | - |
dc.citation.endPage | 65 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | ANTIANGIOGENESIS | - |
dc.subject.keywordPlus | INTERLEUKIN-12 | - |
dc.identifier.url | https://www.nature.com/articles/gt201786 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.